Literature DB >> 16545723

Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.

Guliang Xia1, Robert L Truitt, Bryon D Johnson.   

Abstract

Regulatory T (T(reg)) cells and host antigen-presenting cells (APCs) have been implicated in graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect after donor lymphocyte infusion (DLI), but their relative contributions remain unclear in early versus long-term complete donor or mixed murine allogeneic hematopoietic stem cell (HSC) chimeras. We have previously demonstrated that donor HSC-derived Thy1(+) T(reg) cells, consisting primarily of CD4(+)CD25(+) cells, play an important role in the suppression of graft-versus-host (GVH) reactivity when DLI is given to complete donor chimeras 28 days after HSC transplantation. Data presented here demonstrate that protection against GVHD exerted by Thy1(+) T(reg) cells is less evident with time and eventually is not required in long-term complete donor chimeras because of an absence of host-type APCs to activate alloreactive T cells. Lethal GVHD was observed when Thy1(+) T(reg) cells were depleted from complete donor chimeras given by DLI at day 28, 35, or 42; however, T(reg) cell depletion and DLI at day 70 no longer induced GVHD-associated mortality. Moreover, the failure of DLI to induce GVHD with T(reg) depletion correlated with a loss of the DLI-induced GVL effect in long-term (day 100) complete donor chimeras. In contrast to the results from complete donor chimeras, GVL reactivity in day 100 mixed chimeras was robust after DLI. Loss of a DLI-induced GVL effect in long-term complete donor chimeras was attributed to the absence of host APCs because the infusion of exogenous host-type dendritic cells partially restored both DLI-induced GVL and GVH reactions in day 100 complete donor chimeras. The GVL and GVH reactions restored by infusion of host dendritic cells in day 100 complete donor chimeras were at least partially regulated by T(reg) cells because transient depletion of CD25(+) cells increased both the GVL effect and the severity of GVHD after DLI. Taken together, these data suggest that T(reg) cells can regulate DLI-induced GVL and GVH reactions in both early and long-term complete donor chimeras, and a state of mixed chimerism is superior to complete donor chimerism because host-type APCs facilitate a DLI-induced GVL effect without severe GVHD.

Entities:  

Mesh:

Year:  2006        PMID: 16545723     DOI: 10.1016/j.bbmt.2005.11.519

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  25 in total

Review 1.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Authors:  Nadira Durakovic; Vedran Radojcic; Mario Skarica; Karl B Bezak; Jonathan D Powell; Ephraim J Fuchs; Leo Luznik
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

3.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.

Authors:  James D Lord; Robert C Hackman; Ted A Gooley; Brent L Wood; Amanda C Moklebust; David M Hockenbery; Gideon Steinbach; Steven F Ziegler; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

4.  Involvement of Hofbauer cells and maternal T cells in villitis of unknown aetiology.

Authors:  J-S Kim; R Romero; M R Kim; Y M Kim; L Friel; J Espinoza; C J Kim
Journal:  Histopathology       Date:  2008-03       Impact factor: 5.087

5.  Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia.

Authors:  Nicole Liberio; Haley Robinson; Melodee Nugent; Pippa Simpson; David A Margolis; Subramaniam Malarkannan; Carolyn Keever-Taylor; Monica S Thakar
Journal:  Pediatr Blood Cancer       Date:  2019-07-31       Impact factor: 3.167

6.  Visualization of immune response kinetics in full allogeneic chimeras.

Authors:  Gregory Elkin; Tatyana B Prigozhina; Shimon Slavin; Olga Gurevitch; Sofia Khitrin; Igor B Resnick
Journal:  Am J Blood Res       Date:  2011-08-22

7.  Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Authors:  R Oostvogels; E Kneppers; M C Minnema; R C Doorn; L E Franssen; T Aarts; M E Emmelot; E Spierings; I Slaper-Cortenbach; K Westinga; E Goulmy; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2016-11-14       Impact factor: 5.483

8.  Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.

Authors:  Hui-Hui Ma; Judy Ziegler; Cuiling Li; Antonia Sepulveda; Ahmed Bedeir; Jennifer Grandis; Suzanne Lentzsch; Markus Y Mapara
Journal:  Cell Immunol       Date:  2011-02-04       Impact factor: 4.868

9.  Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation.

Authors:  Melissa Weiss; Daniel Steinbach; Felix Zintl; James Beck; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-06       Impact factor: 4.553

Review 10.  Prevention of allograft rejection by amplification of Foxp3(+)CD4(+)CD25(+) regulatory T cells.

Authors:  Guliang Xia; Malathi Shah; Xunrong Luo
Journal:  Transl Res       Date:  2008-12-25       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.